TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18 years.~2. Able to give written, informed consent~3. Structural heart disease.~4. Implanted and normally functioning ICD or undergoing ICD implant at index admission.~5. Undergoing initial radiofrequency ablation procedure for sustained monomorphic VT.~6. Receiving a class III AADs prior to VT ablation.~7. No VT inducible at the end of VT ablation.~8. No VT inducible on non-invasive programmed stimulation following VT ablation.~Exclusion Criteria:~1. LV assist device in place~2. Decompensated heart failure and/or requiring continuous inotropic therapy and/or awaiting cardiac transplantation~3. Ongoing acute coronary syndrome.~4. Mechanical prosthetic aortic and mitral valves.~5. Pedunculated or mobile left ventricular thrombus.~6. Persistent VT at the end of index catheter ablation.~7. Absolute contraindications for class III AADs.~8. Participation in other trial.~9. VT induced on NIPS after VT ablation.~10. Another reason for continuation of class III AADs (i.e., atrial fibrillation).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuation of antiarrhythmic drugs (Type: EXPERIMENTAL): Patients will continue the class III antiarrhythmic drug they were receiving prior the VT catheter ablation for 3 months after the ablation.
- Discontinuation of antiarrhythmic drugs (Type: NO_INTERVENTION): Patients will stop class III antiarrhythmic drug they were receiving prior to the VT catheter ablation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Systematic Assessment of Functional Ability, Development of Rehabilitation Plan and Follow-up at Home for Elderly Medical Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients admitted to, Medical Visitation Section (MVA) Aarhus University Hospital~* aged 65+~* resident in City of Aarhus.~Exclusion Criteria:~* Patients admitted from a psychiatric institution or nursing home~* patients without walking ability~* patients who do not speak or read Danish~* terminally ill patients~* patients transferred to other hospital departments

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Usual care
- Functional assessment (Type: EXPERIMENTAL): Assessment of functional ability in combination with follow-up at home

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Medicoeconomic Evaluation of Two Surgical Techniques for Lobectomy in the Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have given their consent~* Any patient with proven or suspected lung cancer treated by lobectomy or segmentectomy.~* Patients with a negative mediastinoscopy or negative  EBUS-EUS  following a PET scan showing uptake in mediastinal lymph nodes in the preoperative examination.~* Age ≥ 18 years~* Patient affiliated to a social security regimen~* Patients with a WHO performance status equal to 0 or 1.~Exclusion Criteria:~* Adults under wardship~* Pregnant or breast-feeding women~* Tumours in contact with the pulmonary artery or developing in the lobar bronchi after bronchial fibroscopy.~* Tumours in contact with the costal periosteum or invading the chest wall~* Tumours invading the mediastinal pleura or structures of the mediastinium (superior vena cava, trachea, the main-stem bronchi, aorta, oesophagus, vertebrae)~* Tumours invading the diaphragm~* Tumours invading the neurovascular structures of the apex (brachial plexus, subclavicular artery, subclavicular vein) causing Pancoast-Tobias syndrome~* Patients with histologically-proven contralateral or supraclavicular lymph node (N3) involvement whatever the harvesting method.~* Patients with a positive mediastinoscopy or positive EBUS-EUS following a PET scan with uptake in one or more mediastinal lymph nodes.~* Patients with metastasis (brain, bone, liver, adrenal glands, contralateral lung, pleura).~* Patients who have undergone neo-adjuvant chemotherapy and/or radiotherapy.~* Patients included in a neo-adjuvant chemotherapy and/or radiotherapy protocol.~* Patients who have already undergone thoracotomy.~* Patients with decompensated heart failure or with a systolic ejection fraction below 30%.~* Patients with severe pulmonary artery hypertension.~* Patients with untreated valve disease.~* Patients with unstable angina despite appropriate treatment.~* Patients with untreated carotid stenosis greater than 70%.~* Patients with histologically proven cirrhosis with various decompensations or who have presented haemoptysis because of oesophageal varicose veins.~* Patients with severe neurological sequellae (hemiplegia, paraplegia, tetraplegia).~* Patients presenting severe psychiatric disorders (dementia, psychosis).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lobectomy or segmentectomy using video-thoracoscopy (Type: EXPERIMENTAL): None
- Lobectomy or segmentectomy using thoracotomy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Liver Regeneration

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* willing and able to provide written informed consent~* No history of liver disease or dysfunction~Exclusion Criteria:~* Patients who receive chemotherapy within the 6 weeks prior to their hepatectomy and/or would be started on active chemotherapy within the first 4 weeks post-hepatectomy.~* Patients requiring long-term anticoagulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: TuLip : Role of the Tumor Environment in Cancer-related Fat Loss

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Programmed surgeries in the abdominal area in the Department of Surgery and Transplantation at Cliniques Universitaires Saint-Luc under the supervision of Prof. Dr. Benoit Navez.~* Hospitalization in the context of surgery~* Caucasian~* Age between 18 and 60 years (included).~* Body mass index less than 30 and greater than or equal to 18.5~* Programmed Nissen fundoplication (to treat hiatal hernia and gastroesophageal reflux) or cholecystectomy (to treat vesicular lithiasis), eventration, or parietal surgery .~* Adults capable of expressing their wishes.~* Understanding French~Exclusion Criteria:~* Body mass index below 18.5 and above 30.~* Patients with cancer, infection, autoimmune or inflammatory disease, metabolic syndrome.~* Patients with beta-blockers, hypoglycemics, anti-diabetics, hypolipidemics.~* Adults unable to express their will.~* Not understanding French~* Patients participating in a clinical trial for a drug treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Patients with BMI < 30 kg/m2 (Type: EXPERIMENTAL): Collection of subcutaneous and visceral adipose tissue pieces of 1-2 cm3 during abdominal surgery procedures

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed relapsed/refractory lymphoid malignancies~* Previously treated with at least 2 therapeutic regimens~* ECOG performance \< 2.~* Life expectancy of at least 3 months~* Adequate renal function~* Adequate hematologic status~* Adequate liver function~* Transfusion independent~Exclusion Criteria:~* Received other therapy (biological or drug) to treat cancer within 4 weeks prior to starting treatment with HGS1029 or who exhibit persistent clinical evidence of cancer treatment toxicity~* The use of systemic corticosteroids within 1 week of starting treatment with HGS1029~* Evidence of active bacterial, viral or fungal infection within 2 weeks before starting treatment with HGS1029~* Known HIV infection~* Positive for hepatitis B surface antigen or positive hepatitis C antibody~* Grade 2 or greater neuropathy~* Pregnant female or nursing mother~* Males or females who do not agree to use effective contraception during the study and through at least 30 days after the last dose of HGS1029

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HGS1029 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment Micro-anatomy of the Menisci and Cartilage After Isolated Acute ACL Injury With MRI at 7T

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Presumed isolated, acute rupture of the anterior cruciate ligament (trauma not older than 4 weeks) diagnosed by high-field MRI (3 Tesla or less) at Balgrist.~* Written informed consent of the study participant~* Age 18 years or older~Exclusion Criteria:~* Previous knee surgery or trauma~* Presence of concomitant meniscal injury on high-field MRI (3 Tesla or less)~* Advanced gonarthrosis (Kellgren-Lawrence score greater than 2).~* Contraindication to the performance of MRI~* Unsigned informed consent~* Inability to follow study procedures (e.g., due to cognitive impairment) or inadequate knowledge of project language~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Isolated Acute Anterior Cruciate Ligament Injury with Ultrahigh Field MRI at 7T (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Amplified Sound Signal to Identify Presence of Carotid and Femoral Stenosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age 19-90 years~* having clinical ultrasound evaluation of carotid or femoral artery~Exclusion Criteria:~* under age 19; over age 90 years

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- adults (Type: None): adults audiodoc use to evaluate for carotid or femoral bruit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with documented disaccharidase assay levels of lactase, sucrase, maltase, and palatinase via EGD disaccharidase assay (DA) performed no more than 1 year prior to enrollment with normal histological interpretation. Eligible subjects will be enrolled into the following study groups based on their documented sucrase level.~* DA Sucrase \< 25 (n=500)~* DA Sucrase 25-35 (n=500)~* DA Sucrase \>55 (n=100)~* At the discretion of the investigator, subject is suspected of CSID and has at least one symptom of diarrhea, abdominal pain, gas/bloating, nausea, or borborygmi at least 3x per week for the past 3 months or more.~* Subject or parent/guardian must provide informed consent/assent prior to any study procedures being performed.~* Subject is a U.S. resident.~* Subject is male or female, ages 6 months to 17 years old.~* Subject/parent or guardian is willing and able to complete necessary study procedures including following study instructions, completing electronic questionnaires via a personal mobile device, attending study visits and, in the Investigator's judgment, is sufficiently stable to participate in the study.~* Subject/ parent or guardian must be able to read or understand the English language.~* Subject or parent/guardian must have their own Android or Apple device for BYOD.~Exclusion Criteria:~* Females who are lactating or pregnant.~* Subjects with allergy to sucrose, yeast, papain, or glycerol.~* Subjects with causes of abdominal pain or altered bowel habits other than CSID such as inflammatory bowel disease, celiac disease, eosinophilic gastrointestinal disorder, pancreatitis, or gastrointestinal bleeding.~* Subjects with a history of diabetes mellitus.~* Subjects with a recent febrile illness (5 days prior to study).~* Subjects that do not have the mental capacity to understand the study requirements and are unable to comply.~* Subject has major physical or psychiatric illness within the last 6 months that in the opinion of the investigator would affect the subject's ability to complete the trial.~* Subject has previously used Sucraid®.~* Subject has uncontrolled systematic disease.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm Open Labeled Commercial Sucraid (Type: EXPERIMENTAL): All subjects will complete a 7-day treatment period of open-labeled FDA approved commercial Sucraid.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of Philadelphia chromosome-positive or BCR-ABL-positive chronic phase chronic myelogenous leukemia (CML)~  * In complete cytogenetic remission confirmed by 2 bone marrows ≥ 1 month apart~ * Minimal residual disease~* Detectable BCR-ABL transcript levels obtained \< 6 months apart AND ≤ 0.5-log lower than the lowest value obtained within the past 6 months~PATIENT CHARACTERISTICS:~* Karnofsky performance status 80-100%~* Bilirubin \< 2 times upper limit of normal (ULN)~* Creatinine \< 1.5 times ULN~* ALT and AST \< 2.5 times ULN~PRIOR CONCURRENT THERAPY:~* Recovered from prior therapy~* No major surgery within the past 4 weeks~* No prior chemotherapy~* No prior immunosuppressive therapy~* No prior corticosteroids~* No prior stem cell transplantation~* No radiotherapy within the past 4 weeks~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Recovery of Hibernating Myocardium in End Stage Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or non-pregnant female \>= 18 years of age.~2. End stage chronic and dilated ischemic cardiomyopathy requiring LVAD support.~3. Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of any study procedures.~Ischemic cardiomyopathy is defined by a LVEF \< 40% and any of the following:~* History of myocardial infarction or revascularization.~* History of angina or chest pain and evidence of scarring in non-invasive imaging studies corresponding to previous myocardial infarction.~* Presence of ≥ 75% stenosis of the left main or proximal left anterior descending artery, or ≥ 75% stenosis of 2 or more epicardial vessels in a patient with unexplained cardiomyopathy.~Exclusion Criteria:~* Pregnant and/or lactating women and women of child bearing potential who are not using acceptable means of contraception. Women of childbearing potential must be using adequate measures of contraception (as determined by the Investigator) to avoid pregnancy and should be highly unlikely to conceive during the study period. Women of childbearing potential must have a negative pregnancy test at screen.~* Patients with acute forms of HF: acute onset of symptoms \< 3 months, no left and right ventricular dilation.~* Other conditions that in the opinion of the Principal Investigator may increase risk to the subject and/or compromise the quality of the clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Oral Glutamine in Patients With Sickle Cell Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Active patient (presently receiving medical care for SCA) at the St. Jude Comprehensive Sickle Cell Center (SJCSCC) or an affiliate or alliance of St Jude. Patient must not be in the high risk category as defined by the SJCSCC. High risk is defined as follows:~* 3 or more admissions and/or emergency department visits for pain within the past 12 months, or;~* 2 or more episodes of acute chest syndrome within the past 24 months, or;~* A combination of pain and ACS events \> 3 within the past 12 months.~* 5-18 years of age~* Diagnosis of Hb SS or HB0Thal~* Weight \>15 kg~* \<50th percentile for height/age or weight/age or weight/ height, or \<90% ideal body weight, or \<90% of BMI for age/ gender.~* Is willing to sign informed consent~Exclusion Criteria~* Patients receiving hydroxyurea or any other anti-sickling agent, chronic transfusion, or nutrition supplements.A nutrition supplement is any high calorie or high protein food additive or oral supplement being used for the purpose of weight gain.~* History of poor compliance (Missing two or more clinic appointments in the past year).~* Renal or liver dysfunction~* Renal dysfunction as defined by serum creatinine \>1.5 times normal for age based on testing lab.~* Hepatic dysfunction as defined by alanine aminotransferase (ALT) \>2 times the upper limit of normal for age based on testing lab.~* Breastfeeding~* Pregnancy.Females of childbearing potential must have negative serum or urine pregnancy test (record date of test).~* Patients enrolled on previous glutamine protocol (SCDGLU).~* Patients who are considered high risk

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 2 (Type: EXPERIMENTAL): Glutamine
- 1 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Somatosensory Evoked Potentials and Pain Thresholds in Term and Preterm-Born Adolescents After Early Exposure to Pain; a Quantitative Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~For all:~* Age 15-18~* Appropriate weight for gestational age (AGA)~* Informed consent signed by the parent~* Presence of one parent during the examination~Premature groups:~* Preterm-born (32-34 weeks of gestation)~* Admitted to the NICU (ventilated vs. non-ventilated)~Full term groups:~* Completed 37 weeks of gestation Pain groups (premature and full term)~* Admitted to the NICU~* Mechanically-ventilated during the first week of life~* Mechanically-ventilated for at least 48 hours~Exclusion Criteria:~* Current use of analgesia~* A chronic illness with current medical treatment~* Cognitive impairment

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- NICU full-term early pain group (Type: None): None
- NICU premature early pain group (Type: None): None
- NICU premature control group (Type: None): None
- Soroka- full-term control group (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues